Oasmia Pharmaceutical AB (STO:OASM) announced on Wednesday that the company and Elevar Therapeutics Inc, a US-based biopharmaceutical company, have signed a global strategic partnership deal regarding the commercialisation of Oasmia's anti-cancer product, Apealea.
This agreement includes milestone payments of up to USD678m, depending on Elevar's achievement of future sales milestones, clinical development milestones and regulatory approval milestones. Also, Elevar will also pay Oasmia double-digit royalties on sales of Apealea and Oasmia will receive USD20m as an upfront payment.
This worldwide partnership between Oasmia and Elevar grants Elevar the exclusive right to commercialise Apealea, a proprietary formulation of paclitaxel, in all global territories, with the exception of countries in which Oasmia and its partners are already present including the Nordics, Baltics, Russia and some other CIS countries in which Oasmia and its partners will continue to drive the commercialisation of the product. This arrangement gives Elevar the right to sub-license Apealea to other strategic partners, including, for example, in Europe.
Elevar will be responsible for all regulatory application processes in its territory, including the submission of the approval application to the FDA in the US.
In addition, this collaboration between the two companies will include a joint steering committee and working teams in order to optimise the global development, launch and commercialisation processes. Reportedly, this partnership will build upon Oasmia's product development strategy for Apealea and exploring possible new indications.
Oasmia will remain in sole control over, and will continue to develop, its proprietary technology platform XR17 for use with active pharmaceutical ingredients other than paclitaxel.
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial